Cancer Incidence of 2,4-D Production Workers by Burns, Carol et al.
Int. J. Environ. Res. Public Health 2011, 8, 3579-3590; doi:10.3390/ijerph8093579 
 
International Journal of 
Environmental Research and 
Public Health 
ISSN 1660-4601 
www.mdpi.com/journal/ijerph 
Article  
Cancer Incidence of 2,4-D Production Workers 
Carol Burns 
1,*, Kenneth Bodner 
1, Gerard Swaen 
2, James Collins 
1, Kathy Beard 
3 and  
Marcia Lee 
4 
1  The Dow Chemical Company, Epidemiology, 1803 Building, Midland, MI 48674, USA;  
E-Mails: kmbodner@dow.com (K.B.); jjcollins@dow.com (J.C.) 
2  Dow Benelux BV, Gaspeldoorn 24, Maastricht, Limburg, 6226WR, The Netherlands;  
E-Mail: gswaen@dow.com 
3  The Dow Chemical Company, Industrial Hygiene, 1803 Building, Midland, MI 48674, USA;  
E-Mail: kkbeard@dow.com 
4  The Dow Chemical Company, Occupational Health, 607 Building, Midland, MI 48674, USA;  
E-Mail: mklee@dow.com 
*  Author to whom correspondence should be addressed; E-Mail: cjburns@dow.com;  
Tel.: +1-989-636-2278; Fax: +1-989-636-1875. 
Received: 1 June 2011; in revised form: 27 August 2011 / Accepted: 30 August 2011 / 
Published: 2 September 2011 
 
Abstract:  Despite  showing  no  evidence  of  carcinogenicity  in  laboratory  animals,  the 
herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) has been associated with non-Hodgkin 
lymphoma (NHL) in some human epidemiology studies, albeit inconsistently. We matched 
an existing cohort of 2,4-D manufacturing employees with cancer registries in three US 
states  resulting  in  244  cancers  compared  to  276  expected  cases.  The  Standardized 
Incidence  Ratio  (SIR)  for  the  14  NHL  cases  was  1.36  (95%  Confidence  Interval  (CI)  
0.74–2.29). Risk estimates were higher in the upper cumulative exposure and duration 
subgroups, yet not statistically significant. There were no clear patterns of NHL risk with 
period of hire and histology subtypes. Statistically significant results were observed for 
prostate  cancer  (SIR  =  0.74,  95%  CI  0.57–0.94),  and  “other  respiratory”  cancers  
(SIR = 3.79, 95% CI 1.22–8.84; 4 of 5 cases were mesotheliomas). Overall, we observed 
fewer cancer cases than expected, and a non statistically significant increase in the number 
of NHL cases. 
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1. Introduction 
The herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) is not genotoxic and has shown no evidence 
of carcinogenicity in laboratory animals [1-5]. However, the carcinogenicity of 2,4-D in humans has 
been  actively  debated  since  an  early  case-control  report  of  non-Hodgkin  lymphoma  (NHL)  and 
herbicide use by farmers [6]. Reviewers determined that the subsequent epidemiologic data of 2,4-D 
were inadequate to “conclude that any form of cancer is causally associated with 2,4-D exposure [7]”. 
Nonetheless, the carcinogenicity of 2,4-D continues to be examined in epidemiology studies. 
Cancer mortality rates of The Dow Chemical Company 2,4-D workers in Midland, Michigan have 
been examined previously [8-10]. No significant excess of overall cancer mortality or NHL mortality 
was observed among the employees engaged in the manufacture and formulation of 2,4-D, although 
the  number  of  expected  deaths  was  small.  The  purpose  of  this  study  was  to  evaluate  the  cancer 
incidence rate in these 2,4-D workers since the last evaluation. The use of incidence data may afford 
greater statistical power than mortality because of the additional surviving cases, while at the same 
time  avoiding  some  potential  disease  misclassification  and  treatment  biases  sometimes  seen  in 
mortality studies [11].  
2. Experimental Section 
The herbicide 2,4-D has been manufactured, formulated and packaged in Midland, Michigan since 
the 1940’s. Using the Midland cohort as reported in 2001 [10], 1316 men were identified who worked 
in the 2,4-D operations at any time between 1945 and 1994, and who were alive on 1 January 1985, 
corresponding to the initiation of the Michigan statewide cancer registry. There were only 50 eligible 
females  in  the  2,4-D  manufacturing  areas  which  were  too  few  to  provide  meaningful  female  risk 
estimates. No additional work history or study subjects were added after 1994.  
As in the mortality investigation of the same cohort, a relative exposure index of 0.005, 0.05, 0.5, or 
5 units was  assigned to each job in 2,4-D operations based on industrial hygiene monitoring  and 
history  of  workplace  practices  [10].  Cumulative  exposure  for  each  individual  was  computed  by 
summing  the  exposure  index  times  job  duration  in  years  over  all  2,4-D  jobs  held  since  1945  as  
unit-years. Since potential for exposure had ceased before the start of follow-up for 75% of the cohort 
members, cumulative exposure was treated as a static variable for analysis. Cohort members were 
assigned to a cumulative exposure group of <1 unit-year, 1–4.99 unit years, or 5+ unit years. The same 
divisions were used to define cumulative duration groups. No additional exposure or work history data 
were added to the cohort since 1994. All jobs in the 1983 to 1994 period were in the lowest exposure 
intensity (very low, or 0.005), therefore all recent jobs would presumably also contribute little new 
exposure to the analysis. 
The Michigan Department of Community Health (MDCH) ascertained incident cases by linking the 
cohort to the Michigan statewide cancer registry. The registry originates from the Michigan Cancer 
Surveillance Program of the Bureau of Local Health and Administrative Services within the MDCH. Int. J. Environ. Res. Public Health 2011, 8  3581 
 
This  statewide  registry  also  incorporates  data  from  the  Metropolitan  Detroit  Cancer  Surveillance 
System, a National Cancer Institute funded registry covering Wayne, Oakland and Macomb counties. 
The International Classification of Disease (ICD) groupings are provided in the Appendix. 
We attempted to identify cancer cases in additional states. Data were linked with cases diagnosed in 
Arizona, a state with known deaths among former Michigan workers [12]. Of the six cases matched by 
this  process,  only  one,  a  prostate  cancer,  was  diagnosed  prior  to  moving  from  Michigan.  Since 
Michigan shares  a border with Ohio, data  were also linked to Ohio, but  yielded no matches.  We 
decided  not  to  search  in  additional  states  because  of  the  high  cost,  cumbersome  regulations,  and 
difficulty in discerning the added person years at risk [13].  
The follow-up period was bounded by the latter of the study start date, 1 January 1985 and the start 
of  work  in  2,4-D,  and  the  earlier  of  the  date  of  death  for  decedents  and  the  end  of  study  date,  
31 December 2007. For cancer cases, person years were allowed to accumulate beyond the diagnosis 
date to allow for the analysis of second primary cancers. Residency dates were additionally considered 
in order to accommodate eligibility requirements of the state cancer registry. All study members were 
considered Michigan residents while working in a Dow Michigan job. Thereafter, company address 
records were available only for those active at another Dow location or eligible for retirement benefits. 
For those members who were found to leave the state prior to 1985, follow-up was delayed until 
Michigan residency was resumed. Person years accrued until the end of study date, the date of death, 
or a permanent non-Michigan address appeared in their personnel records, whichever occurred first.  
A  terminated  employee  with  no  address  record  was  assumed  to  remain  in  the  state  following  his 
Michigan location service. Decedents whose death certificates cited Michigan as the state of residency 
were determined to be eligible for study until their date of death. This was defined as Cohort 2. 
In order to describe the minimum and maximum person years at risk alternative conditions were 
applied to create Cohorts 1 and 3. For Cohort 1, residency requirements were removed and all subjects 
accrued person years until the end of study or death. For Cohort 3, the most restrictive conditions were 
applied to halt follow-up at the date of the subject’s last known Michigan address, often earlier but 
never later than the Cohort 2 end of follow-up. For example, a person who retired in 1975 with a 
Michigan address in 1995 would have 10 person years at risk (1985 to 1995). Another person who also 
left employment in 1975 but with no addresses on file would be excluded from this cohort. Cancer 
risks were analyzed and presented for all 3 cohorts. 
Standardized  incidence  ratios  (SIR)  for  all  cancers  and  specific  cancers  were  computed  using 
Michigan State rates for white males as the background. Statistical significance was determined using 
the 95% Fisher's exact confidence interval (95% CI) based on the Poisson distribution. For Cohort 2 
only, parallel analyses were performed using alternative comparison areas: the SEER (Surveillance 
Epidemiology and End Results) registry population of Wayne, Oakland and Macomb counties, as well 
as  a  regional  population  of  local  (Midland,  Saginaw  and  Bay)  counties.  Additional  analyses  by 
cumulative exposure and cumulative duration groups used Cohort 2 and state rates. Tests for trend 
were performed according to Breslow and Day [14]. 
Study conduct was reviewed and overseen by a Human Studies Review Board and the MDCH 
Institutional Review Board. To maintain privacy of the cancer cases, all analyses were conducted by 
the MDCH and no identifiable case data were released to the company investigators. 
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3. Results and Discussion 
More than half of the workers were less than 50 years of age at the start of follow-up (Table 1). 
However, most were hired prior to the Michigan tumor registry and start of follow-up (1985). Very 
few racial minorities were represented in the cohort. Duration of employment in the 2,4-D operations 
ranged from 2 days to 34 years and cumulative exposure ranged from less than 1 to 103 units of  
unit-years. 
Table 1. Selected characteristics of 2,4-D production workers in Cohort 2. 
Age at start of follow-up  People  % 
19–29  118  9.4 
30–39  345  27.5 
40–49  304  24.2 
50–59  245  19.5 
60–69  196  15.6 
70+  48  3.8 
Total  1256   
Period of hire     
<1960  422  33.6 
1960–1985  514  40.9 
>1985  320  25.5 
Total  1256   
Race     
White  1208  96.2 
Black  23  1.8 
Hispanic  22  1.8 
American Indian  3  0.2 
Total  1256   
Person years at risk (PYAR) continued for persons diagnosed with cancer beyond the diagnosis 
date. If employees were known to have moved out of state, the PYAR ended at the time their 
address was known to be outside of Michigan. 
Cancer incidence results and person years of follow-up for each of the 3 cohorts are presented in 
Table  2.  The  numbers  of  person  years  at  risk  were  greatest  for  Cohort  1  and  least  for  Cohort  3, 
corresponding to the different constraints on follow-up. By definition, the percent censored for Cohort 1 
was zero. The expected numbers were at their maximum, based on Michigan cancer rates. On the other 
hand,  the  censored  population  was  13.5%  in  Cohort  3.  This  ultraconservative  approach  ended 
residency at the termination of employment for many workers and disqualified many others who had 
sparse address information. Cohorts 1 and 3 provide the upper and lower bounds for expected values. 
Further details are presented only for Cohort 2. Int. J. Environ. Res. Public Health 2011, 8  3583 
 
Table 2. Cancer incident cases by primary site, 1985–2007 compared to Michigan White Males. 
 
Cohort 1 
N = 1316, PY = 25,267 
Cohort 2 
N = 1256, PY = 23,354 
Cohort 3 
N = 1108, PY 18,897 
Cancer  Obs  Exp  SIR  95% CI  Obs  Exp  SIR  95% CI  Obs  Exp  SIR  95% CI 
All Cancer  246  305.85  0.80  0.71–0.91  244  276.08  0.88  0.78–1.00  211  219.55  0.96  0.84–1.10 
Lip, oral and pharynx  8  8.96  0.89  0.38–1.76  8  8.14  0.98  0.42–1.94  7  6.43  1.09  0.44–2.24 
Stomach  5  5.21  0.96  0.31–2.24  4  4.70  0.85  0.23–2.18  3  3.74  0.80  0.16–2.34 
Colon  17  23.36  0.73  0.42–1.17  17  21.03  0.81  0.47–1.29  16  16.76  0.95  0.55–1.55 
Rectum  9  10.70  0.84  0.38–1.60  9  9.67  0.93  0.42–1.77  6  7.68  0.78  0.29–1.70 
Pancreas  2  6.64  0.30  0.03–1.09  2  5.99  0.33  0.04–1.21  2  4.76  0.42  0.05–1.52 
Other GI and Digestive  8  10.91  0.73  0.32–1.44  8  9.86  0.81  0.35–1.60  8  7.82  1.02  0.44–2.02 
Larynx  5  4.96  1.01  0.32–2.35  5  4.49  1.11  0.36–2.60  4  3.55  1.13  0.30–2.88 
Lung and Bronchus  41  54.51  0.75  0.54–1.02  40  49.15  0.81  0.58–1.11  36  39.04  0.92  0.65–1.28 
Other Respiratory *  5  1.46  3.42  1.10–7.99  5  1.32  3.79  1.22–8.84  5  1.05  4.76  1.53–11.11 
Bone and soft tissue  1  1.70  0.59  0.01–3.27  1  1.54  0.65  0.01–3.61  1  1.24  0.81  0.01–4.49 
Melanoma of skin  9  9.34  0.96  0.44–1.83  9  8.50  1.06  0.48–2.01  8  6.77  1.18  0.51–2.33 
Breast  1  0.66  1.52  0.02–8.43  1  0.60  1.67  0.02–9.27  0  0.47  0   
Prostate gland  62  93.44  0.66  0.51–0.85  62  84.11  0.74  0.57–0.94  51  66.86  0.76  0.57–1.00 
Other genital *  3  1.87  1.60  0.32–4.69  3  1.74  1.72  0.35–5.04  3  1.44  2.08  0.42–6.09 
Urinary bladder  22  21.73  1.01  0.63–1.53  22  19.57  1.12  0.70–1.70  19  15.59  1.22  0.73–1.90 
Kidney and renal pelvis  8  9.14  0.88  0.38–1.72  8  8.29  0.97  0.42–1.90  5  6.57  0.76  0.25–1.78 
Other urinary *  3  0.93  3.23  0.65–9.43  3  0.84  3.57  0.72–10.44  3  0.67  4.48  0.90–13.08 
Brain and other CNS  3  3.78  0.79  0.16–2.32  3  3.43  0.87  0.17–2.54  3  2.75  1.09  0.22–3.19 
Hodgkin’s disease  1  1.03  0.97  0.01–5.40  1  0.95  1.05  0.01–5.86  1  0.77  1.30  0.02–7.23 
Non-Hodgkin lymphoma  14  11.34  1.23  0.67–2.07  14  10.27  1.36  0.74–2.29  14  8.18  1.71  0.93–2.87 
Multiple myeloma  2  3.52  0.57  0.06–2.05  2  3.17  0.63  0.07–2.28  2  2.52  0.79  0.09–2.87 
Leukemias  7  8.04  0.87  0.35–1.79  7  7.25  0.96  0.39–1.98  5  5.79  0.86  0.28–2.02 
All other  10  12.63  0.79  0.38–1.46  10  11.42  0.88  0.42–1.61  9  9.11  0.99  0.45–1.88 
Cohort 1 assumes the entire cohort remained in Michigan through December 31, 2007; For Cohort 2, person years at risk (PYAR) continued for persons diagnosed with cancer 
beyond the diagnosis date. If employees were known to have moved out of state, the PYAR ended at the time their address was known to be outside of Michigan; Cohort 3 was 
restricted to employees considered to be Michigan residents for the entire period; * Other Respiratory include 1 carcinoma of the sinuses, 4 mesothelioma; Other Genital 
include 1 penis, 2 testis; Other Urinary include 1 urethra, 2 ureter. Int. J. Environ. Res. Public Health 2011, 8  3584 
 
 
There were 244 incident cancers among the 1256 men of Cohort 2 (SIR = 0.88, 95% CI 0.78–1.00). 
There were 29 individuals with two independent primary cancer diagnoses and two individuals with 
three diagnoses each. We observed 14 cases of NHL compared to 10.27 expected (SIR = 1.36, 95% CI 
0.74–2.29). The most common cancers were prostate (n = 62, SIR = 0.74, 95% CI 0.57–0.94), lung  
(n = 40, SIR = 0.81, 95% CI 0.58–1.11), and bladder (n = 22, SIR = 1.12, 95% CI = 0.70–1.70), 
representing more than half the cancer cases. Significantly greater than expected were 5 cases of “other 
respiratory”  cancer  compared  to  1.32  expected  (SIR =  3.79,  95%  CI  =  1.22–8.84).  This  category 
excludes cancers of the larynx, bronchus, trachea, and lung. It includes the nasal cavity, accessory 
sinuses, pleura, and other sites. Analyses of Cohort 2 using local and SEER comparisons differed little 
from the state wide comparisons. 
The NHL cumulative exposure group and cumulative duration group analyses were limited by the 
small sample size and none was statistically significant (Table 3). Most of the subjects had worked less 
than a year and were in the lowest duration category. The highest SIR occurred among the workers 
with the longest duration. Results were similar for cumulative exposure analyses. There was little 
change in SIR by period of hire. 
Table 3. Observed and expected numbers of NHL by groups, Cohort 2, 1985–2007. 
Exposure measure  People  Observed  Expected  SIR  95% CI 
Duration (years)           
<1  770  7  6.50  1.08  0.43–2.22 
1–4.99  338  3  2.47  1.21  0.25–3.55 
5+  148  4  1.30  3.08 *  0.84–7.88 
Intensity x duration 
(exposure years) 
         
<1  1001  9  7.25  1.24  0.57–2.36 
1–4.99  149  2  1.63  1.23  0.15–4.43 
5+  106  3  1.39  2.16 *  0.45–6.31 
Decade of Hire           
1945–1949  181  4  2.54  1.57  0.43–4.03 
1950–1959  241  4  3.06  1.31  0.36–3.35 
1960–1969  305  4  2.25  1.78  0.48–4.56 
1970–1979  255  2  1.47  1.36  0.17–4.92 
1980–1989  167  0  0.69  0.00  0.00–5.35 
1990–1994  107  0  0.26  0.00 *  0.00–14.19 
* P test for trend for duration (p = 0.12), exposure years (p = 0.46) and decade of hire (p = 0.43); 
Person years at risk (PYAR) continued for persons diagnosed with cancer beyond the diagnosis 
date. If employees were known to have moved out of state, the PYAR ended at the time their 
address was considered to be outside of Michigan. 
Employees engaged in the manufacture or formulation of 2,4-D experienced a decreased risk of 
overall cancer incidence when compared to statewide rates. There were slightly more NHL cancers 
than  expected.  We  did  observe  some  increase  in  risk  with  increasing  duration  and  cumulative 
exposure, but not by decade of hire. However, these findings were based on a small number of cases 
and none was statistically significant. A breakdown by histological subtype revealed 7 mature B-cell Int. J. Environ. Res. Public Health 2011, 8  3585 
 
lymphomas; 6 malignant lymphomas not otherwise specified; and 1 cutaneous T-cell lymphoma. No 
subtype was concentrated in the highest exposure category and no etiologic pattern was suggested.  
In  1986,  the  International  Agency  for  Cancer  Research  (IARC)  classified  the  chlorophenoxy 
herbicides as Group 2B (possible) carcinogens [15]. This monograph evaluated the group, which in 
addition to 2,4-D, includes other herbicides such as 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and 
related impurities of polychlorinated dioxins. No human classification was made for 2,4-D. Since this 
review, other cohorts of phenoxy herbicide manufacturers and applicators have found no increased 
cancer mortality or incidence due to NHL [16-18]. A recent update of manufacturers observed a hazard 
ratio of 0.92 (95% CI 0.19–4.47) for deaths due to NHL in 2,4-D exposed factory workers [19]. A 
pooled analysis of several case-control studies also found no association between NHL and the use of 
2,4-D [20]. Mechanistic and toxicological research indicates that increased cancer risk from 2,4-D 
exposure does not appear biologically plausible [1,2]. The findings of our study in the context of other 
research are not sufficient to support a relationship between 2,4-D exposure and NHL risk.  
A  statistically  significant  risk  deficit  for  prostate  cancer  was  observed  in  the  manufacturing 
workers. Consistent with patterns in the US and Michigan, prostate cancer was the most commonly 
occurring  cancer  in  the  current  cohort  [21].  Some  agricultural  cohorts  have  indicated  a  positive 
association  between  prostate  cancer  and  either  2,4-D  [22],  or  pesticide  use  in  general  [23].  The 
previous  mortality  report  of  this  group  of  manufacturing  workers  identified  more  prostate  cancer 
deaths than expected (7 vs. 5) [10]. Since an industry study of triazine workers observed higher risk 
ratios for prostate cancer incidence than for mortality, presumably due to early screening practices, we 
anticipated similar results [24]. However, the SIR of 0.74 in the current study was significantly lower 
than expected (62 incident prostate cancers vs. 84 expected). It is unclear why prostate cancer is less 
common in the current 2,4-D cohort than the comparison populations. These results are consistent with 
the nested case-control  study of 55,332 applicators in the Agricultural  Health Study, in  which no 
positive association of 2,4-D use and prostate cancer was reported [25]. Unlike the Agricultural Health 
Study, we had no information on risk factors other than age and race. Since only white males were 
used in the comparison rates, and there were some black males in the 2,4-D operations, any resulting 
bias from not including race in our study should have been toward higher rates [20].  
Also unexpected was the excess risk of other respiratory cancers. Four of the five cancer cases in 
this  category  were  mesotheliomas.  Whereas  mesothelioma  is  strongly  associated  with  asbestos 
exposure [26], it has not been linked with 2,4-D. Notably, the Midland location has been in operation 
since 1897 and deaths due to mesothelioma have been previously reported at this site [12]. Because 
identification  of  the  incident  cases  was  precluded  due  to  the  confidentiality  agreement  with  the 
MDCH, we were unable to scrutinize their job histories. However, it is conceivable that these four 
individuals were exposed to asbestos long ago in other departments at the site, in other jobs off-site, or 
in other non-occupational settings.  
This  finding  illustrates  a  disadvantage  of  this  occupational  cohort,  as  well  as  other  phenoxy 
herbicide cohorts, that is, the potential for co-exposures to multiple pesticides and industrial chemicals. 
With respect to NHL, exposures to other industrial chemicals at this site are also likely, that might 
increase risk [27-29]. Since the causal role of environmental risk factors for NHL is largely unknown, 
the contributions of other exposures are unclear [30]. Int. J. Environ. Res. Public Health 2011, 8  3586 
 
Exposure  was  estimated  by  years  worked  in  2,4-D  operations  and  also  by  a  cumulative  
duration-intensity index. While these relative measures of exposure may not be optimal, they and the 
job  records  used  in  this  study  have  several  advantages  over  the  episodic  exposures  reported  by 
agricultural  workers  [31].  Whereas  turf  applicators  spray  fairly  continuously  throughout  a  season, 
exposure estimation from their job records is often inadequate [32]. In a reliability study of farmer 
applicators, respondents had a high percentage of agreement on ever using 2,4-D, but for more detailed 
questions such as years mixed or applied and days per year mixed or applied, the exact agreement was 
only 50 percent [33]. The current occupational cohort is strengthened by the documentation of start 
and stop dates and department assignments, thereby eliminating biases due to recall or observation. 
Further, exposures in manufacturing are likely more continuous over the course of the year than those 
in farm applications. Farmer applicators apply 2,4-D during a limited season which may amount to 
only a few days or weeks per year. Manufacturing workers may also have the opportunity for higher 
daily  exposure.  Repeated  biomonitoring  of  German  2,4-D  manufacturing  workers  from  a  single 
production plant between 1985 and 1989 found that most of the production workers had mean daily 
exposures  less  than  50  µg/kg/day  [34].  This  is  in  contrast  to  geometric  mean  dose  levels  of  
2.5 µg/kg/day in US farmer applicators [35,36]. Although it is not certain that the German data are 
representative of all manufacturers, their exposures are well below the rodent cancer bioassay No 
Observable Effect Level (NOEL) of 150 mg/kg/day (the top dose tested) [37]. The large separation 
between  worker  exposures  and  NOEL  doses  in  rodent  toxicity  studies,  coupled  with  the  lack  of 
genotoxicity  activity of  2,4-D, further supports a lack of biological plausibility for possible 2,4-D 
induced human cancer. 
Critical to the interpretation of this study is the axiom that all cancer cases in Michigan residents 
appear  in  the  Michigan  registry,  and  that  cancers  among  non-Michigan  residents  are  excluded. 
Therefore, the main uncertainty in the study is not ascertainment, but rather determination of person 
years  at  risk.  We  attempted  to  circumscribe  this  uncertainty  by  the  use  of  alternative  follow-up 
definitions based on more or less constrictive use of available address data. These constraints altered 
the expected numbers such that the highest were in Cohort 1, the least restricted, and the lowest were 
in Cohort 3, the most restricted. The data for all three cohorts are presented in Table 2. In this manner 
the reader can observe the maximum and minimum person years at risk for this population and the 
related expected number of cancers for all causes. We expected that the SIRs would similarly follow 
so that the SIRs in Cohort 1 would be the smallest and those of Cohort 3 would be the largest, thus 
creating a range from lowest to highest risk in Cohorts 1, 2 and 3. This occurred for most cancer types. 
One might consider Cohort 3 to be the most representative of true risk to the employees because all 
person years required documentation of residency. However, this conservative approach censored 14% 
of Michigan cancer cases, who were definitely Michigan residents at the time of diagnosis, resulting in 
an unexpected lowered SIR for cancers of the stomach, rectum, breast, kidney, and leukemias. The 
cohort  was  also  smaller  than  Cohort  2  by  148  fewer  men  and  4457  fewer  person  years,  further 
reducing the statistical power.  
The  construction  of  Cohort  2  permitted  including  person  years  between  the  end  of  Michigan 
employment and address changes. Nonetheless, some downward bias of the SIR may have resulted if 
the person years at risk were overestimated. The impact of this bias, however, must be less than the 
SIR as reported in Cohort 3. The higher SIRs would not change the overall conclusions. For example, Int. J. Environ. Res. Public Health 2011, 8  3587 
 
the all cancer SIRs in Cohort 2 (SIR = 0.88, 244 observed vs. 276 expected) and Cohort 3 (SIR = 0.96, 
211 observed vs. 220 expected) were both below the null value. The SIRs for prostate cancer were also 
similarly below 1.0, although the SIR in Cohort 3 was borderline significant (SIR = 0.76, 95% CI  
0.57–1.00). The statistically significant SIR of 3.79 (95% CI 1.22–8.84) for other respiratory cancers 
in Cohort 2, was higher in Cohort 3 (SIR = 4.76) but the confidence interval was less precise (95% CI 
1.53–11.11). There were 14 cases of NHL in all three Cohorts. The risk estimate for this cancer could 
be as high as 1.71, per Cohort 3. However, the etiology and role of 2,4-D is no more clear than the SIR 
of 1.36 in Cohort 2. 
Because the choice of control population could also affect risk estimates, we also employed three 
different comparison populations, three counties, the three urban counties in the Detroit metropolitan 
areas defined by SEER, as well as the full state, with little resultant change in SIRs. With complete 
Michigan  cancer  ascertainment  and  judicious  censoring  of  person  years  at  risk,  we  found  little 
evidence of significant bias attributable to low case ascertainment.  
4. Conclusions 
We observed no excess of overall cancer in this occupational cohort engaged in the manufacture 
and formulation of 2,4-D. This is consistent with the toxicology and experimental data for 2,4-D. 
Prostate  cancer,  the  most  common  cancer  in  the  cohort,  was  significantly  reduced  compared  to 
background  rates.  Similar  to  the  previous  mortality  study  done  at  the  same  site,  we  found  no 
statistically significant risk of NHL. 
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